John Wiley & Sons, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a WLY research report →
Price Chart
About the company
John Wiley & Sons, Inc. , a publisher, provides authoritative content, data-driven insights, and knowledge services for the advancement of science, innovation, and learning in the United States, China, the United Kingdom, Japan, Australia, and internationally. The company’s Research segment provides scientific, technical, medical, and scholarly journals, as well as related content and services in the areas of physical sciences and engineering, health sciences, social sciences, and humanities, and life sciences.
- CEO
- Matthew S. Kissner
- IPO
- 1972
- Employees
- 4,500
- HQ
- Hoboken, NJ, US
AI snapshot
Six angles, distilled from the data.
The stock is in a constructive multi-month uptrend, trading above its 200-day average of 44.86 and slightly above its 50-day average of 50.01. It sits well below the 52-week high of 57.03 but far above the 52-week low of 27.72, pointing to a mid-cycle consolidation rather than a broken trend.
Street sentiment is cautious-to-positive: the consensus sits at Hold, while the average target of 68 implies meaningful upside from current levels. Coverage is thin, with one Buy and two Holds, and the last recorded rating action was an upgrade in 2022, so the setup leans on valuation and execution rather than fresh analyst momentum.
The earnings profile is mixed but still workable. Wiley has beaten in 5 of the last 7 quarters, yet the most recent completed quarter missed by 17.0%, so shareholders should watch for margin discipline and whether the next print confirms the 2026 EPS step-up toward 4.75.
No notable discretionary insider buying or selling. Recent activity is dominated by awards, an exempt exercise, and a gift transfer, which are not the same as open-market conviction; the only clearly directional item is a 25,000-share gift from a 10% owner.
Profitability is solid, with a 74.6% gross margin, 16.97% operating margin, and 11.9% net margin. Growth is uneven: revenue fell 2.6% year over year, but EPS growth was 108.4%, supported by strong free cash flow of 344.4 million and a 13.32% FCF yield.
Wiley looks steadier than many publishing peers because of its high gross margin, low beta of 0.741, and durable cash generation. The valuation is not demanding at 11.86 times earnings, which leaves room if the company keeps converting margin strength into EPS growth.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.34B
- P/E
- 12.36
- Fwd P/E
- 9.61
- PEG
- 0.11
- P/S
- 1.42
- P/B
- 2.97
- EV/EBITDA
- 9.59
- Div Yield
- 3.06%
- Gross Margin
- 75.40%
- Op Margin
- 14.75%
- Net Margin
- 11.90%
- ROE
- 25.28%
- ROIC
- 9.94%
Latest fiscal year · YoY change
- Revenue
- $1.68B-0.1%
- Gross Profit
- $1.25B+4.2%
- Op Income
- $276.86M
- Net Income
- $221.62M+163.3%
- EPS
- $4.22+170.5%
- OCF Growth
- +28.6%
- FCF Growth
- +47.5%
- 52W High
- $57.45
- 52W Low
- $28.38
- 50D MA
- $50.07
- 200D MA
- $45.15
- Beta
- 0.74
- RSI (14)
- 32
- Avg Volume
- 451.92K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Wiley said Q1 matched expectations, with research and AI momentum offset by a known prior-year AI comparison and softer learning demand, while reaffirming full-year guidance.· September 3, 2026
- Research revenue rose 4% to $293 million, with research publishing up 12% and research adjusted EBITDA margin up 130 basis points to 29.6%.
- AI revenue was $14 million in the quarter, with another $14 million already contracted for Q2 and Q3; management said it remains on track for over $50 million in fiscal 27.
- Learning revenue fell 20% to $93 million, hurt by prior-year AI licensing comparisons, softer retail/consumer demand, and weaker professional and assessments trends.
- Emerald contributed $13 million to the top line, and integration is running ahead of schedule with synergy capture underway.
- Management reaffirmed full-year guidance for organic revenue growth, margin, EPS, and free cash flow.
- The company raised its dividend for the 33rd consecutive year and returned $33 million through dividends and repurchases.
Wiley reported Q1 research revenue of $293 million, up 4%, and learning revenue of $93 million, down 20%. Research publishing grew 12%, while research solutions declined 30%; research adjusted EBITDA was $87 million, up 9%, with margin up 130 basis points to 29.6%. Learning adjusted EBITDA was $14 million with margin at 15.1%. AI revenue was $14 million in the quarter, Emerald contributed $13 million to the top line, adjusted EPS was down 10%, and GAAP EPS was a loss of $0.23 versus earnings of $0.22 a year ago. Full-year guidance was reaffirmed for organic revenue growth of low to mid single digits, research growth at mid single digits, adjusted EBITDA margin of 26.5% to 27.5%, adjusted EPS of $4.60 to $5.05, and free cash flow of $205 million.
Matthew Kissner framed the quarter as consistent with expectations and emphasized that Wiley is building on fiscal 26 momentum by scaling research and AI-related revenue streams. He stressed that the company’s trusted content is becoming more central to high-stakes AI and highlighted new external validation, including Wiley’s role in the DOE Genesis Mission and as a founding data partner for Cusp AI’s Global Materials Foundry. His tone was confident and strategic, repeatedly returning to the idea of a “Wiley flywheel” linking publishing and AI, while saying the full-year outlook was unchanged.
Craig Albright said the year-over-year decline was driven mainly by the prior-year AI license comparison, with the remainder tied to the seasonally light learning period. He cited research adjusted EBITDA of $87 million, up 9%, margin expansion to 29.6%, corporate expenses down 19% to $33 million, free cash flow use of $70 million versus $100 million a year ago, and trailing net debt to EBITDA of 2.7x, or 2.1x pro forma including Emerald synergies. He also said CapEx was $14 million in Q1 and is expected to be approximately $80 million for the year, and reiterated Emerald expectations including $30 million of synergies by year 3.
Analysts focused on whether research organic growth excluding AI and Emerald was competitive, the cadence of AI revenue through the year, Emerald integration progress, the monetization path for partnerships like IQVIA and open evidence, and the weakness in learning. Management said research is growing in line with market leaders, with long-term market growth around 3% to 4%, and that AI deals remain lumpy but are tracking to expectations, with another $14 million contracted across Q2 and Q3. On Emerald, management said there were no surprises and that the integration is ahead of plan. On learning, they pointed to tough Amazon inventory comparisons in professional books, soft sell-through, and weaker assessments, but said inclusive access and courseware remain growth drivers.
The call showed clear momentum in research, where submissions were up 31%, output up 8%, retention stayed above 99%, and open access and advanced journals are expanding. Management also highlighted multiple growth engines outside core publishing, including $14 million of AI revenue in Q1, a growing clinical outcome assessments business, and early traction in audience monetization. Emerald was described as strategically and culturally a strong fit, with integration ahead of schedule.
Learning remains a drag, with revenue down 20% and management still dealing with prior-year Amazon inventory effects, softer retail demand, and weak assessments. AI licensing is still lumpy and dependent on timing, which management acknowledged when discussing quarter-to-quarter variability. The company also noted higher net interest expense from Emerald and a first-half pattern where free cash flow is typically a use of cash.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 75.5%
- Shares Outstanding
- 50.68M
- Float Shares
- 38.25M
of shares held by institutions
267 13F filers
Buy/sell ratio 6.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 6.20M | ▲ 37.72K |
| Vanguard Group Inc | 4.84M | ▲ 25.17K |
| Neuberger Berman Group LLC | 3.02M | ▲ 2.14K |
| Vanguard Portfolio Management LLC | 2.49M | ▼ 7.73K |
| Lsv Asset Management | 2.44M | ▲ 1.42M |
| Schroder Investment Management Group | 2.43M | ▲ 51.83K |
| State Street Corp | 2.31M | ▲ 51.06K |
| Dimensional Fund Advisors LP | 1.89M | ▲ 3.22K |
| Vanguard Capital Management LLC | 1.67M | ▼ 53.08K |
| Bank Of Montreal /Can/ | 1.59M | ▲ 9.19K |
| Brown Advisory Inc | 1.27M | ▲ 57.24K |
| Geode Capital Management, LLC | 992.27K | ▼ 13.95K |
Held by 305 ETFs
Biggest fund positions in WLY by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 17, 26 | Scognamiglio Frank | other | 2,055 |
| Oct 22, 26 | Singh Inder M | other | 122 |
| Oct 22, 26 | Dobson David C | other | 228 |
| Oct 22, 26 | Hemphill Brian O | other | 114 |
| Oct 22, 26 | Andresen Katherine Dunn | other | 47 |
| Oct 22, 26 | Madden Karen N | other | 55 |
| Oct 22, 26 | MCDANIEL RAYMOND W | other | 439 |
| Oct 13, 26 | WILEY DEBORAH E | other | 25,000 |
| Sep 23, 26 | PESCE WILLIAM J | other | 3,275 |
| Sep 24, 26 | PESCE WILLIAM J | other | 2,880 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our WLY coverage
Recent articles, reports, and earnings notes.

John Wiley & Sons (WLY): AI Monetization and Margin Expansion
Wiley pairs a resilient Research franchise with growing AI monetization and meaningful margin improvement. Learning remains a drag, but cash flow, digital mix, and Emerald synergies support a Hold view.

John Wiley & Sons, Inc. (WLY) gains on deep earnings beat
John Wiley & Sons, Inc. (WLY) gained after a fiscal Q1 earnings beat, but the deeper story is in the mix: strong research publishing, improving AI revenue, and Emerald synergies offset Learning weakness. We break down margins, guidance, and what the reversal means for the stock.

John Wiley & Sons, Inc. (WLY) gains on earnings beats
John Wiley & Sons, Inc. (WLY) gains 3.0% after reporting earnings beats, as investors react positively to the company’s stronger-than-expected quarterly results.
Want a deeper read on WLY?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Wiley and Abridge Partner to Bring the Evidence that Informs Clinical Guidelines Worldwide into the Abridge Assistant
businesswire.com · Nov 16
John Wiley & Sons (WLY) Could Be a Great Choice
zacks.com · Nov 5
Wiley Accelerates Growth of World-Renowned Advanced Portfolio with Four New Research Journal Launches
businesswire.com · Oct 27
Counterpoint Mutual Funds LLC Buys New Shares in John Wiley & Sons, Inc. $WLY
defenseworld.net · Oct 18
Dividend Champion, Contender, And Challenger Highlights: Week October 4
seekingalpha.com · Oct 2
John Wiley & Sons (WLY) Could Be a Great Choice
zacks.com · Oct 1
Corient Private Wealth LP Purchases 16,889 Shares of John Wiley & Sons, Inc. $WLY
defenseworld.net · Sep 25
Wiley Announces Quarterly Dividend; Leader in Trusted Content and Research Intelligence Raised Dividend for 33rd Consecutive Year in June 2026
businesswire.com · Sep 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 18, 2026 · Live quote · Not investment advice